ETIDIOH - NEW

  Ann Intern Med MARCUCCI M, Chan MTV, Painter TW, Efremov S, et al Effects of a Hypotension-Avoidance Versus a Hypertension-Avoidance Strategy on Neurocognitive Outcomes After Noncardiac Surgery. Ann Intern Med. 2025 Jun 3. doi: 10.7326/ANNALS-24-02841. PubMed           Abstract available GOLDMAN JM, Moyer DV Flying the Plane While Building It: Lessons From the COVID-19 Pandemic. Ann Intern Med. 2025 Jun 3. doi: 10.7326/ANNALS-25-02436. PubMed          Antiviral Res MALUNE P, Esposito F, Tramontano E Unveiling SARS-CoV-2's heart: role, structure and inhibition of SARS-CoV-2 RNA-dependent RNA polymerase. Antiviral Res. 2025 Jun 3:106208. doi: 10.1016/j.antiviral.2025.106208. PubMed           Abstract available BMJ MURPHY F Covid-19: New variant spreading across Asia is found in UK. BMJ. 2025;389:r1161. PubMed          LOOI MK Trump wa...

  BMC Pediatr ALRASHED R, Almeshawi I, Alshammari A, Alhamoud W, et al Burden of bronchiolitis post-COVID-19 pandemic in children less than 2 years old in 2021-2024: experience from a tertiary center in Saudi Arabia. BMC Pediatr. 2025;25:453. PubMed           Abstract available BIGLARI HN, Ahmadi A, Alidousti K, Pouredalati M, et al Growth in the first two years in children born to mothers infected with COVID-19 during pregnancy: a cohort study. BMC Pediatr. 2025;25:448. PubMed           Abstract available CHENG J, Wu Y, Ma H, Tang M, et al C-reactive protein and serum amyloid A protein as complementary biomarkers in differentiating viral and bacterial community-acquired pneumonia in children. BMC Pediatr. 2025;25:445. PubMed           Abstract available J Gen Virol CAPELASTEGUI F, Goldhill DH H5N1 2.3.4.4b: a review of mammalian adaptations and risk of pandemic e...

  By Kabelleger / David Gubler (http://www.bahnbilder.ch) -  http://www.bahnbilder.ch/pictures/medium/8253.jpg , CC BY-SA 3.0,  https://commons.wikimedia.org/w/index.php?curid=16836731 Source: Wikipedia,  https://en.wikipedia.org/wiki/FS_Class_ALn_772 ____

Summary Background Onradivir (ZSP1273) is a potent inhibitor of the PB2 subunit of influenza A virus (IAV) polymerase . Our previous, phase 2 clinical trial showed that a 600 mg regimen of onradivir initiated within 48 h of symptom onset can expedite the recovery of adult patients from acute, uncomplicated influenza. Here, we aimed to evaluate the safety and therapeutic efficacy of onradivir in a larger group with acute, uncomplicated influenza. Methods This randomised, double-blind, multicentre, placebo-controlled and oseltamivir-controlled, phase 3 trial was conducted at 68 clinical sites in China . Eligible participants were adults (aged 18–64 years) with an influenza-like illness who screened positive by rapid IAV antigen testing at the first clinical visit, and had a fever (axillary temperature ≥38·0°C) with at least one moderate systemic and one moderate respiratory symptom within 48 h of symptom onset. Patients were randomly assigned into three treatment groups, stratified by in...

{Excerpt} After the spread of SARS-CoV-2 JN.1, its subvariants, such as KP.3 (JN.1.11.1.3)1 and KP.3.1.1 (JN.1.11.1.3.1.1),2 and XEC (a recombinant lineage of two JN.1 subvariants),3 emerged and rapidly spread globally. Subsequently, LP.8.1 (JN.1.11.1.1.1.3.8.1),4 a descendant lineage of KP.1.1.3 (JN.1.11.1.1.1.3), accounts for approximately 30% of all global infections as of April, 2025 , as per data from Nextstrain. Thereafter, NB.1.8.1 (XDV.1.5.1.1.8.1), a descendant lineage of XDV , has started to spread worldwide. XDV is a recombinant lineage of XDE (a recombinant lineage of GW.5.1 [XBB.1.19.1.5.1] and FL.13.4 [XBB.1.9.1.13.4]) and JN.1. NB.1.8.1 has acquired seven spike substitutions and 23 non-spike substitutions compared with JN.1 (appendix pp 15–16). Compared with the XEC spike protein, the NB.1.8.1 spike bears four substitutions : G184S, K478I, A435S, and L1104V (appendix pp 15–16). We estimated the relative effective reproduction number (Re) of NB.1.8.1 using a Bayesian mult...

Abstract Seasonal influenza viruses continue to pose a significant threat, causing substantial morbidity and mortality in the US and worldwide despite the availability of vaccines and antivirals. These challenges may be addressed by improving vaccine immunogenicity through the inclusion of adjuvants that enhance immune responses against key antigens including influenza hemagglutinin (HA). BECC (Bacterial Enzymatic Combinatorial Chemistry) adjuvants are novel Toll-like Receptor 4 (TLR4) ligands created by modifying enzymes from lipid A synthesis pathways in Gram-negative bacteria. This study compares the ability of the biological and synthetic versions of these adjuvants to enhance the efficacy of recombinant HA (rHA) antigens in mouse influenza virus challenge . Mice immunized with rHA adjuvanted with BECCs stimulate the humoral and cell-mediated arms of the immune system without exhibiting cytotoxicity/pyrogenicity. A robust HA-specific immunoglobulin subtype, especially IgG2a, respon...

Abstract The influenza A virus polymerase, consisting of a heterotrimer of three viral proteins, carries out both transcription and replication of the viral RNA genome . These distinct activities are regulated by viral proteins that vary in abundance during infection, and by various co-opted host cell proteins, which serve as targets for the development of novel antiviral interventions . However, little is known about which host proteins direct transcription and which replication. In this report, we performed a differential interactome screen to identify host proteins co-opted as either transcription- or replication-specific factors. We found that distinct sets of host proteins interact with the influenza polymerase as it carries out the different activities. We functionally characterised HMGB2 and RUVBL2 as replication-specific cofactors and RPAP2 as a transcription-specific cofactor. Our data demonstrate that comparative proteomics can be used as a targeted approach to uncover virus-...